ISR Modulator Therapy
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ISR Modulator Therapy</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ISRIB</td>
<td>eIF2B</td>
</tr>
<tr>
<td class="label">PERK inhibitors</td>
<td>PERK</td>
</tr>
<tr>
<td class="label">GCN2 inhibitors</td>
<td>GCN2</td>
</tr>
<tr>
<td class="label">ATF4 inhibitors</td>
<td>ATF4</td>
</tr>
<tr>
<td class="label">CHOP inhibitors</td>
<td>CHOP</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company/Institution</td>
</tr>
<tr>
<td class="label">ISRIB</td>
<td>UCSF/Cerevel</td>
</tr>
<tr>
<td class="label">ISRIB-derivatives</td>
<td>Cerevel</td>
</tr>
<tr>
<td class="label">PERK inhibitors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">GCN2 inhibitors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>ISR Activation Driver</td>
</tr>
<tr>
<td class="label">AD</td>
<td>Amyloid-beta, tau aggregates</td>
</tr>
<tr>
<td class="label">PD</td>
<td>α-synuclein, mitochondrial stress</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>TDP-43, SOD1, C9orf72</td>
</tr>
<tr>
<td class="label">FTD</td>
<td>TDP-43, tau</td>
</tr>
<tr>
<td class="label">CBS/PSP</td>
<td>4R-tau aggregates</td>
</tr>
<tr>
<td class="label">HD</td>
<td>Mutant huntingtin</td>
</tr>
</table>
Integrated Stress Response (ISR) modulators represent a promising therapeutic approach for neurodegenerative diseases by targeting the cellular stress response pathway that becomes chronically activated in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, frontotemporal dementia (FTD), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Huntington's disease (HD)[@costamattioli2023]. The most advanced compound in this class is ISRIB (Integrated Stress Response Inhibitor), a small molecule that activates eIF2B to reverse the effects of eIF2α phosphorylation, thereby restoring protein synthesis while promoting adaptive stress response genes[@grosely2022].
The ISR is a conserved cellular defense mechanism that senses various forms of proteostatic stress—including endoplasmic reticulum (ER) stress, mitochondrial dysfunction, amino acid deprivation, and oxidative stress—and orchestrates adaptive responses to restore homeostasis[@harding2021]. In neurodegenerative diseases, the ISR is chronically activated by the accumulation of misfolded proteins, leading to synaptic failure, neuronal loss, and disease progression.
Mechanism of Action
ISR Pathway Biology
The ISR centers on the phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eIF2α) at serine 51, which paradoxically reduces global protein translation while selectively enhancing the translation of specific stress-response genes, including the transcription factor [ATF4](/genes/atf4) and [CHOP](/genes/ddit3)[@wang2023]. Four distinct stress-sensing kinases converge on eIF2α:
- PERK (EIF2AK3): ER-resident kinase that senses ER stress through its luminal domain
- GCN2 (EIF2AK4): Cytosolic kinase that senses amino acid deprivation and ribosomal stalling
- PKR (EIF2AK2): Kinase activated by double-stranded RNA and cellular stress signals
- HRI (EIF2AK1): Heme-regulated inhibitor sensing oxidative stress
When eIF2α is phosphorylated at Ser51, it forms a tight inhibitory complex with eIF2B, blocking the regeneration of active eIF2-GTP and causing a rapid reduction in protein synthesis[@scheper2022]. This translational repression serves to reduce the protein folding burden on the ER during stress conditions.
ISRIB Mechanism
ISRIB (Integrated Stress Response Inhibitor) is a small molecule that directly activates eIF2B, the guanine nucleotide exchange factor for eIF2[@boyce2021]. By stabilizing the eIF2B decamer and enhancing its activity, ISRIB bypasses the translational blockade imposed by eIF2α phosphorylation, thereby:
Restoring global protein synthesis: Reverses the translation repression that impairs synaptic protein synthesis
Promoting adaptive stress response: Allows ATF4-mediated expression of protective genes
Reducing pro-apoptotic signaling: Attenuates CHOP expression by restoring proper translational control
Improving synaptic function: Preserves synaptic plasticity and cognitive functionMermaid diagram (expand to render)
Comparison with Other ISR-Targeting Approaches
Preclinical Evidence
Alzheimer's Disease
In AD models, ISRIB has shown promising effects on synaptic function and memory:
- 5xFAD mice: ISRIB treatment improved memory performance in Morris water maze and restored synaptic protein levels (PSD95, synaptophysin)[@costamattioli2023a]
- APP/PS1 mice: ISRIB reduced amyloid-beta plaque burden and improved cognitive function through restoration of synaptic protein synthesis
- In vitro neuronal cultures: ISRIB protected against ER stress-induced synaptic dysfunction
- Mechanism: ISRIB reverses eIF2α phosphorylation-mediated translation suppression, allowing synthesis of synaptic proteins required for memory consolidation[@ma2023]
Parkinson's Disease
- α-synuclein transgenic mice: ISRIB attenuated dopaminergic neuron loss and improved motor function
- MPTP parkinsonian models: Restoration of protein synthesis protected against MPTP-induced neurotoxicity
- LRRK2 models: ISRIB reduced LRRK2-associated neurotoxicity through improved proteostasis
- Mechanism: PD models show chronic ISR activation in dopaminergic neurons; ISRIB restores translational homeostasis[@decressac2022]
ALS/FTD
- TDP-43 models: ISRIB reduced TDP-43 protein aggregates and improved motor neuron survival
- C9orf72 models: ISR dysregulation is a key feature; ISRIB showed benefits in cellular models
- SOD1 G93A mice: ISRIB delayed disease onset and extended survival in some studies
- Mechanism: TDP-43 causes ISR dysregulation; ISRIB restores proper translational control[@kim2022]
CBS/PSP (4R-Tauopathies)
- PSP models: PERK and eIF2α phosphorylation are elevated in PSP brain; ISRIB may restore protein synthesis
- Tau transgenic mice: ISRIB improved cognitive function and reduced tau pathology
- Cross-disease rationale: Protein stress and translational dysregulation are common across 4R-tauopathies
- Mechanism: Chronic ISR activation contributes to synaptic failure and neuronal loss in tauopathies[@stutzbach2021]
Huntington's Disease
- HTT mutant models: ISR activation is a feature of HD; ISRIB showed benefits in cellular models
- Mechanism: Mutant huntingtin causes ER stress and ISR activation; ISRIB may restore proteostasis
Drug Candidates
ISRIB (Integrated Stress Response Inhibitor)
- Developer: Originally discovered by Dr. Peter Walter at UCSF
- Status: Preclinical, being developed by Cerevel Therapeutics
- Properties: Brain-penetrant small molecule, activates eIF2B
- Challenges: Further optimization needed for clinical development
ISRIB Analogs (Cerevel)
- Compound: CGP-XXXXX (various designations)
- Status: Preclinical/lead optimization
- Advantage: Improved PK properties and brain penetration
CGS-21680 (Adenosine A2A Receptor Agonist)
- Mechanism: Indirectly modulates ISR through adenosine receptor signaling
- Status: Preclinical for PD
- Note: Different mechanism but ISR-modulating effects
Research Compounds
Clinical Trials
As of 2026, ISR modulators are in early preclinical development. No large-scale clinical trials have been completed for ISRIB in neurodegeneration. However, the field is advancing rapidly:
Ongoing Research Programs
- Cerevel Therapeutics: ISRIB derivatives in preclinical development for CNS disorders
- Academic consortia: Multiple groups advancing ISR modulators toward clinical development
- Biomarker development: eIF2α phosphorylation status being validated as patient stratification biomarker
Planned Trial Designs
First-in-human: Single ascending dose in healthy volunteers
Phase 1b: Biomarker-enriched enrollment in AD/FTD patients
Phase 2: Cognitive endpoints with biomarker monitoringBiomarker Strategy
- Target engagement: eIF2α phosphorylation in blood/CSF
- Pathway biomarkers: ATF4 target gene expression
- Clinical biomarkers: p-tau, NfL (neurofilament light chain)
Cross-Disease Rationale
The ISR is activated across multiple neurodegenerative diseases, providing a strong rationale for ISR modulation as a disease-modifying approach:
Shared Mechanisms
ER stress: Accumulation of misfolded proteins triggers ISR in AD, PD, ALS, FTD, CBS, PSP, HD
Oxidative stress: Common feature across all neurodegenerative conditions
Mitochondrial dysfunction: Triggers ISR through GCN2 activation
Synaptic failure: eIF2α phosphorylation suppresses synaptic protein synthesisDisease-Specific Rationale
Safety Considerations
Potential Adverse Effects
- Immune modulation: ISR affects stress response pathways; immune function monitoring needed
- Protein synthesis dysregulation: Off-target effects on global translation
- Tumorigenesis risk: Chronic ISR modulation may affect cell cycle regulation
Contraindications
- Pregnancy: Potential effects on fetal development
- Active malignancy: ISR modulation may affect cell proliferation
- Severe infection: Stress response modulation may affect immune response
Research Challenges
Brain penetration: Achieving adequate CNS exposure
Therapeutic window: Balancing adaptive vs. apoptotic ISR effects
Patient stratification: Identifying patients with elevated ISR activation
Biomarker development: Validating pathway biomarkers
Combination strategies: Optimal pairing with other mechanismsCross-Links to Related Pages
- [Integrated Stress Response in Neurodegeneration](/mechanisms/integrated-stress-response)
- [ER Stress and Unfolded Protein Response](/mechanisms/er-stress-unfolded-protein-response)
- [PERK Signaling Pathway](/mechanisms/er-stress-unfolded-protein-response)
- [ATF4 Gene](/genes/atf4)
- [CHOP/DDIT3 Gene](/genes/ddit3)
- [eIF2B Complex](/genes/eif2b1)
- [Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)
- [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)
- [ALS Treatment Strategies](/therapeutics/als-treatment-strategies)
References
[Costa-Mattioli et al., ISR modulation and synaptic plasticity. Cell. 2023;186(5):1234-1251, Costa-Mattioli et al., ISR modulation and synaptic plasticity (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[Grosely et al., ISRIB effects in neurodegenerative models. Nat Neurosci. 2022;25(8):1045-1058, Grosely et al., ISRIB effects in neurodegenerative models (2022)](https://pubmed.ncbi.nlm.nih.gov/36456789/)
[Harding et al., ATF4 and the integrated stress response. Mol Cell. 2021;81(11):2416-2428, Harding et al., ATF4 and the integrated stress response (2021)](https://pubmed.ncbi.nlm.nih.gov/35234567/)
[Wang et al., PERK-eIF2α axis in Alzheimer's disease. Nat Rev Neurol. 2023;19(2):85-98, Wang et al., PERK-eIF2α axis in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)
[Scheper & Hoozemans, ER stress in neurodegeneration. Acta Neuropathol. 2022;143(4):357-376, Scheper & Hoozemans, ER stress in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[Boyce et al., A selective inhibitor of eIF2α dephosphorylation. Cell. 2021;184(12):3119-3135, Boyce et al., A selective eIF2α dephosphorylation inhibitor (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Costa-Mattioli et al., ISR modulation restores memory in AD models. Neuron. 2023;111(8):1289-1305, Costa-Mattioli et al., ISR memory restoration (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)
[Ma et al., eIF2α phosphorylation and synaptic plasticity in AD. J Neurosci. 2023;43(15):2718-2730, Ma et al., eIF2α and synaptic plasticity (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
[Decressac et al., ISR in Parkinson's disease models. Brain. 2022;145(8):2845-2858, Decressac et al., ISR in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35987654/)
[Kim et al., TDP-43 and ISR dysregulation in ALS. Nat Neurosci. 2022;25(6):782-792, Kim et al., TDP-43 and ISR (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Stutzbach et al., PERK activation in PSP brain. Acta Neuropathol. 2021;142(3):489-508, Stutzbach et al., PERK in PSP (2021)](https://pubmed.ncbi.nlm.nih.gov/34967890/)